Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.48 |
| ▸ | VNN1 | O95497 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791987 | 0.84 | VNN1 (0.49) | CYP1A2CYP2C19CYP3A4CLK4VNN1 | |
| SCHEMBL6283187 | 0.82 | MAP4K4 (0.48) | — | |
| SCHEMBL1192525 | 0.80 | BRAF (0.53) | — | |
| SCHEMBL28884642 | 0.80 | FYN (0.59) | — | |
| SCHEMBL29933870 | 0.80 | FYN (0.59) | — | |
| SCHEMBL3143358 | 0.78 | CDK2 (0.57) | CYP1A2CYP2C19CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL4014599 | 0.77 | CDK2 (0.60) | — | |
| SCHEMBL1981974 | 0.77 | CTSB (0.48) | CYP1A2CYP2C19CYP3A4CLK4VNN1 | |
| SCHEMBL1678795 | 0.75 | LTA4H (0.53) | CYP1A2CYP2C19CYP3A4CLK4HSD17B10 | |
| SCHEMBL5207658 | 0.75 | CLK4 (0.51) | CLK4ALDH1A1TSHRMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CYP1A2 340/4885CYP2C19 440/4885CYP3A4 1391/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CYP1A2 340/4885CYP2C19 440/4885CYP3A4 1391/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | CYP1A2 364/4885CYP2C19 452/4885CYP3A4 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.